hepatitis-c

Documents about hepatitis-c

• Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan#1046842ClinicalTrials.gov
• Diagnosis and treatment coverage among hepatitis C infections in Denmark, 2022: a capture-recapture study using national registers#398558Figshare
• Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)#861883ClinicalTrials.gov
• A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment#872249ClinicalTrials.gov
• A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection#916282ClinicalTrials.gov
• Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection#969457ClinicalTrials.gov
• The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study#800855ClinicalTrials.gov
• HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function#810082ClinicalTrials.gov
• Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients#847145ClinicalTrials.gov
• The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)#849115ClinicalTrials.gov
• TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing#858138ClinicalTrials.gov
• A Methadone Maintenance Treatment Outcome Study in Three Provinces in China#907086ClinicalTrials.gov
• Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)#841437ClinicalTrials.gov
• Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults#911681ClinicalTrials.gov
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen#991991ClinicalTrials.gov
• Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort#675885eScholarship
• "She Was Real About It and Made Me Feel Life Is Important": Patient Perspectives on Peers' Role in Peer-Assisted Telemedicine Hepatitis C Treatment for People Who Use Drugs in Rural Communities.#251385NCBI PubMed Central
• Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid#803613ClinicalTrials.gov
• HCV Self-testing in Georgia#829636ClinicalTrials.gov
• HCV-related cryoglobulinemic vasculitis (mixed cryoglobulinemia syndrome) in the era of direct-acting antivirals: A 10-year experience from Italian tertiary referral centers#231820IRIS
• HEPATITIS C POINT-OF-CARE TESTING AND TREATMENT IN PEOPLE WITH SERIOUS MENTAL ILLNESS: A COHORT STUDY OF COMMUNITY OUTPATIENTS (REACH OUT)#422571Figshare
• Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver#326559KOASAS: KAIST Open Access Self-Archiving System
• Informing the Equitable Implementation of Hepatitis C Interventions: Cost-Effectiveness Modeling in Rural Populations of People Who Inject Drugs#479681Springer Nature OA
• Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy#833564ClinicalTrials.gov
• Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens#874720ClinicalTrials.gov
• Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)#915405ClinicalTrials.gov
• A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection#995022ClinicalTrials.gov
• MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV#876448ClinicalTrials.gov
• Association between neighborhood-level overall social vulnerability and cumulative incidence of reported hepatitis C virus infection in Los Angeles County from 2018 to 2023#1053138Europe PMC
• Social Network Characteristics as Predictors of Opioid Use Disorder Treatment Utilization among People Who Use Drugs with Hepatitis C Infections in Baltimore, MD#337307Figshare
• Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects#830975ClinicalTrials.gov
• SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection#909419ClinicalTrials.gov
• VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.#876698ClinicalTrials.gov
• Correlation between the mechanical and histological properties of liver tissue#954704Koc University Digital Collections
• A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A#1033241ClinicalTrials.gov
• Neurocognitive impairment with hepatitis C and HIV co-infection in Southern Brazil#634634eScholarship
• Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)#851349ClinicalTrials.gov
• Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis#807916ClinicalTrials.gov
• A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients#890928ClinicalTrials.gov
• Relationship between serum viral load and stages of hepatic fibrosis in patients with chronic hepatitis C virus infections in Plateau State, Nigeria: Relation entre la charge virale sérique et les stades de fibrose hépatique chez les patients atteints d'une infection chronique par le virus de l'hépatite C dans l'État de Plateau, au Nigéria#329007African Journals Online
• Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection#190648UNSWorks Repository
• Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment#675828eScholarship
• Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project#901315ClinicalTrials.gov
• Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3#887881ClinicalTrials.gov
• Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health#614695eScholarship
• Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection#843011ClinicalTrials.gov
• Frecuencia de infección por hepatitis C mediante detección del antígeno core utilizando el inmunoanálisis quimioluminiscente Architect HCV Ag en donantes de sangre del Instituto Nacional de Enfermedades Neoplásicas, 2020#977193Repositorio Universidad Peruana Cayetano Heredia